Fact CheckerSign in

NCT06435260RecruitingPhase 2

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

To Explore the Efficacy of Hypofractionated Radiotherapy Followed by AG Regimen Chemotherapy Plus Camrelizumab Immunotherapy as Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Cancer

Source: ClinicalTrials.gov · Last updated 6 Jul 2026

Brief summary (registry, in English)

The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
30 (estimated)
First submitted
24 May 2024
Start date
1 Aug 2024
Primary completion date
1 Jun 2025
Lead sponsor
Hebei Medical University Fourth Hospital
NCT number
NCT06435260

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 30
  • From 1 Aug 2024 to the primary completion date, 1 Jun 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Poor cognitive ability, inability to answer questions, inability to fill out questionnaires, or mental disorders;

Other

  • Patients who did not meet these inclusion criteria;
  • The investigators think inappropriate.

Who the study is looking for

  • Age:18 to 75 years old, male or female;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
  • Tumor was located in the pancreas;
  • Pathological diagnosis was pancreatic ductal adenocarcinoma or acinar cell carcinoma;
  • No distant metastasis;
  • The pancreatic tumor is located more than 1cm away from the duodenum;
  • Clinical assessment was locally advanced or critical for resectable.
    • Locally advanced pancreatic cancer diagnostic criteria: (1) due to tumor invasion, venous occlusion or involving a wide range of superior mesenteric vein branch of jejunum, cannot safely - superior mesenteric vein reconstruction. ② (pancreatic head/uncinate process tumors) tumor contact with superior mesenteric artery or celiac artery \> 180°. Tumor contact with superior mesenteric artery or coeliac trunk artery \> 180°, tumor contact with coeliac trunk artery and invasion of abdominal aorta.
    • Critical for resectable pancreatic cancer diagnostic criteria: (1) contact with portal vein tumor - superior mesenteric vein \> 180 °, 180 ° or less or contact combined intravenous contour irregular or venous thrombosis, but safety is complete resection and reconstruction; The tumor contacted the inferior vena cava. ② (pancreatic head/uncinate process tumors) the tumors contacting the common hepatic artery, but not involving the celiac artery or the origin of the left and right hepatic arteries, can be completely resected and safely reconstructed; Superior mesenteric artery tumor contact 180 ° or less; The tumor contacts the aberrant arteries (such as accessory right hepatic artery, alternative right hepatic artery, alternative common hepatic artery, etc.). (pancreatic body and tail tumors) tumor contact with superior mesenteric artery ≤180°; Tumor contact with celiac artery ≤180°; 7.There was no history of immune system diseases, other malignant tumors, myocarditis, coronary heart disease, other cardiovascular and cerebrovascular diseases, thyroid dysfunction, liver and kidney diseases, psychiatric diseases, infectious diseases, or systemic diseases other than those mentioned above.
    • Participants were willing to join in this study, good adherence and written informed consent.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Fourth Hospital of Hebei Medical University
Coordinator of this site? Confirm its status
ShijiazhuangChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.